Atrial fibrillation in essential hypertension: An issue of concern

Journal of Cardiovascular Medicine

Volumn 15, Issue 2, 2014, Pages 100-106

  Zhao, Li Qun ^a   Liu, Shao Wen ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

atrial fibrillation; atrial remodeling; hypertension; trigger activity

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; DISEASE COURSE; ESSENTIAL HYPERTENSION; HEART ATRIUM FIBRILLATION; HEART ATRIUM REMODELING; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PREVENTION; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; HEART RATE; HUMANS; HYPERTENSION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896716125     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283640ff7     Document Type: Review

References (60)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018-1022.
2. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98:476-484.
3. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344:101-106.
4. Nieuwlaat R, Capucci A, Camm AJ. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26:2422-2434.
5. Yildirir A, Batur MK, Oto A. Hypertension and arrhythmia: blood pressure control and beyond. Europace 2002; 4:175-182.
6. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612-2617.
7. Singh JP, Larson MG, Tsuji H, Evans JC, O'Donnell CJ, Levy D. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension 1998; 32:293-297.
8. Warren SE, O'Connor DT, Cohen IM. Autonomic and baroreflex function after captopril in hypertension. Am Heart J 1983; 105:1002-1008.
9. Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation 2008; 118:916-925.
10. Burashnikov A, Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 2003; 107:2355-2360.
11. Boldt A, Wetzel U, Weigl J, et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42:1785-1792.
12. Goette A, Staack T, Rö cken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35:1669-1677.
13. Rogg H, de Gasparo M, Graedel E, et al. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J 1996; 17:1112-1120.
14. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and-independent pathways. Cardiovasc Res 2003; 60:315-325.
15. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27:136-149.
16. Das UN. Is angiotensin-II an endogenous proinflammatory molecule? Med Sci Monit 2005; 11:RA155-RA162.
17. Tanabe Y, Kawamura Y, Sakamoto N, Sato N, Kikuchi K, Hasebe N. Blood pressure control and the reduction of left atrial overload is essential for controlling atrial fibrillation. Int Heart J 2009; 50:445-456.
18. Thomas MC, Dublin S, Kaplan RC, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008; 21:1111-1116.
19. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009; 119:2146-2152.
20. Pierdomenico SD, Lapenna D, Cuccurullo F. Risk of atrial fibrillation in dipper and nondipper sustained hypertensive patients. Blood Press Monit 2008; 13:193-197.
21. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003; 108:668-671.
22. Loaldi A, Pepi M, Agostoni PG, et al. Cardiac rhythm in hypertension assessed through 24 h ambulatory electrocardiographic monitoring. Effects of load manipulation with atenolol, verapamil, and nifedipine. Br Heart J 1983; 50:118-126.
23. Madu EC, Baugh DS, Gbadebo TD, Dhala A, Cardoso S, Phi-Res Multi-Study Group. Effect of ethnicity and hypertension on atrial conduction: evaluation with high-resolution P-wave signal averaging. Clin Cardiol 2001; 24:597-602.
24. Vranka I, Penz P, Duká t A. Atrial conduction delay and its association with left atrial dimension, left atrial pressure and left ventricular diastolic dysfunction in patients at risk of atrial fibrillation. Exp Clin Cardiol 2007; 12:197-201.
25. Fukunami M, Yamada T, Ohmori M, et al. Detection of patients at risk for paroxysmal atrial fibrillation during sinus rhythm by P wave-triggered signalaveraged electrocardiogram. Circulation 1991; 83:162-169.
26. Guidera SA, Steinberg JS. The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation. J Am Coll Cardiol 1993; 21:1645-1651.
27. Stafford PJ, Turner I, Vincent R. Quantitative analysis of signal-averaged P waves in idiopathic paroxysmal atrial fibrillation. Am J Cardiol 1991; 68:751-755.
28. Faggiano P, D'Aloia A, Zanelli E, Gualeni A, Musatti P, Giordano A. Contribution of left atrial pressure and dimension to signal-averaged P-wave duration in patients with chronic congestive heart failure. Am J Cardiol 1997; 79:219-222.
29. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7:833-842.
30. Solti F, Vecsey T, Ké kesi V, Juhász-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989; 23:882-886.
31. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997; 96:1686-1695.
32. Kistler PM, Sanders P, Dodic M, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006; 27:3045-3056.
33. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100:87-95.
34. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81:512-525.
35. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999; 84:776-784.
36. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kü hlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44:121-131.
37. Gaspo R, Bosch RF, Bou-Abboud E, Nattel S. Tachycardia-induced changes in Na\+ current in a chronic dog model of atrial fibrillation. Circ Res 1997; 81:1045-1052.
38. Tedesco MA, Di Salvo G, Ratti G, Natale F, Iarussi D, Iacono A. Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. Clin Cardiol 2001; 24:603-607.
39. Appleton CP, Galloway JM, Gonzalez MS, Gaballa M, Basnight MA. Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. J Am Coll Cardiol 1993; 22:1972-1982.
40. Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002; 39:739-743.
41. Matsuda M, Matsuda Y. Mechanism of left atrial enlargement related to ventricular diastolic impairment in hypertension. Clin Cardiol 1996; 19:954-959.
42. Dreslinski GR, Frohlich ED, Dunn FG, Messerli FH, Suarez DH, Reisin E. Echocardiographic diastolic ventricular abnormality in hypertensive heart disease: atrial emptying index. Am J Cardiol 1981; 47:1087-1090.
43. Smith VE, Schulman P, Karimeddini MK, White WB, Meeran MK, Katz AM. Rapid ventricular filling in left ventricular hypertrophy: II. Pathologic hypertrophy. J Am Coll Cardiol 1985; 5:869-874.
44. Inouye I, Massie B, Loge D, et al. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. Am J Cardiol 1984; 53:120-126.
45. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32:197-204.
46. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98:2765-2773.
47. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: populationbased estimates. Am J Cardiol 1998; 82:2N-9N.
48. Wachtell K, Gerdts E, Aurigemma GP, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press 2010; 19:169-175.
49. Eckardt L, Kirchhof P, Breithardt G, Haverkamp W. Load-induced changes in repolarization: evidence from experimental and clinical data. Basic Res Cardiol 2001; 96:369-380.
50. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167:73-79.
51. Lau DH, Mackenzie L, Kelly DJ, et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm 2010; 7:1282-1290.
52. Schotten U, Duytschaever M, Ausma J, Eijsbouts S, Neuberger HR, Allessie M. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation 2003; 107:1433-1439.
53. Ausma J, Litjens N, Lenders MH, et al. Time course of atrial fibrillationinduced cellular structural remodeling in atria of the goat. J Mol Cell Cardiol 2001; 33:2083-2094.
54. Yu WC, Lee SH, Tai CT, et al. Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man. Cardiovasc Res 1999; 42:470-476.
55. Lau DH, Mackenzie L, Kelly DJ, et al. Short-term hypertension is associated with the development of atrial fibrillation substrate: a study in an ovine hypertensive model. Heart Rhythm 2010; 7:396-404.
56. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55:2299-2307.
57. Goette A, Schö n N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012;43-51.
58. Yamashita T, Inoue H, Okumura K, et al., J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13:473-479.
59. Zhou X, Du JL, Yuan J, et al. Statins therapy can reduce the risk of atrial fibrillation in patients with acute coronary syndrome: a meta-analysis. Int J Med Sci 2013; 10:198-205.
60. Loffredo L, Angelico F, Perri L, et al. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord 2012; 12:107.